SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct. 25, 2012--
Exelixis, Inc. (NASDAQ: EXEL) will release its third quarter 2012
financial results on Wednesday, November 7, 2012, after the markets
close. The announcement will be followed by a live webcast at 5:00 p.m.
EST/ 2:00 p.m. PST. During the webcast, Exelixis management will discuss
the Company’s financial results, financial outlook, and development
program and plans for cabozantinib, and also provide a general business
update. The webcast may be accessed in the Event Calendar page under
Investors at http://www.exelixis.com.
An archived replay of the webcast will be available on the Event
Calendar page under Investors at http://www.exelixis.com
and via phone until 11:59 p.m. PST on December 7, 2012. Access numbers
for the phone replay are: 888-286-8010 (domestic) and 617-801-6888
(international); the passcode is 43220636.
About Exelixis
Exelixis, Inc. is a biotechnology company committed to developing small
molecule therapies for the treatment of cancer. Exelixis is focusing its
proprietary resources and development efforts exclusively on
cabozantinib (formerly known as XL184), its most advanced product
candidate, in order to maximize the therapeutic and commercial potential
of this compound. Exelixis has also established a portfolio of other
novel compounds that it believes have the potential to address serious
unmet medical needs, many of which are being advanced by partners as
part of collaborations. For more information, please visit the company's
web site at www.exelixis.com.
Source: Exelixis, Inc.
Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President,
Investor Relations and Corporate Communications
cbutler@exelixis.com
